PT700430E - Processo para estimular selectivamente a proliferacao das celulas t - Google Patents
Processo para estimular selectivamente a proliferacao das celulas tInfo
- Publication number
- PT700430E PT700430E PT94919346T PT94919346T PT700430E PT 700430 E PT700430 E PT 700430E PT 94919346 T PT94919346 T PT 94919346T PT 94919346 T PT94919346 T PT 94919346T PT 700430 E PT700430 E PT 700430E
- Authority
- PT
- Portugal
- Prior art keywords
- cells
- cell proliferation
- selectively stimulating
- stimulating
- agent
- Prior art date
Links
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 230000006052 T cell proliferation Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 5
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7322393A | 1993-06-04 | 1993-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT700430E true PT700430E (pt) | 2005-07-29 |
Family
ID=22112479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT94919346T PT700430E (pt) | 1993-06-04 | 1994-06-03 | Processo para estimular selectivamente a proliferacao das celulas t |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP0700430B1 (pt) |
JP (2) | JPH08511166A (pt) |
AT (1) | ATE293686T1 (pt) |
AU (1) | AU7052194A (pt) |
CA (1) | CA2164226C (pt) |
DE (1) | DE69434342T2 (pt) |
DK (1) | DK0700430T3 (pt) |
ES (1) | ES2240962T3 (pt) |
HK (1) | HK1014734A1 (pt) |
PT (1) | PT700430E (pt) |
WO (1) | WO1994029436A1 (pt) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
EP0764203A1 (en) * | 1994-06-03 | 1997-03-26 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY | Methods for selectively stimulating proliferation of t cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
EP0824594B1 (en) * | 1995-05-04 | 2005-04-06 | The United States of America as Representend by The Secretary of the Navy | Improved methods for transfecting t cells |
AU762356B2 (en) * | 1995-05-04 | 2003-06-26 | Regents Of The University Of Michigan, The | Improved methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
WO1997005239A1 (en) * | 1995-07-25 | 1997-02-13 | Celltherapy, Inc. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
DE19722888A1 (de) * | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
AU8777898A (en) * | 1997-08-11 | 1999-03-01 | Chiron Corporation | Methods for genetically modifying t cells |
ZA989497B (en) | 1997-10-20 | 2000-04-19 | Roche Diagnostics Gmbh | Positive-negative selection in homologous recombination. |
JP2001522806A (ja) * | 1997-11-10 | 2001-11-20 | アーチ・デヴェロップメント・コーポレイション | エクス・ビボ活性化t細胞を用いる腫瘍および腫瘍細胞の処理方法 |
FI974321A0 (fi) * | 1997-11-25 | 1997-11-25 | Jenny Ja Antti Wihurin Rahasto | Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa |
IL147972A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc Ge | Pd-1, a receptor for b7-4 and uses therefor |
JP2003534283A (ja) * | 2000-05-25 | 2003-11-18 | エクサイト セラピーズ, インコーポレイテッド | 天然で誘導されたかまたは人工的に誘導された免疫抑制後にt細胞免疫サーベイランスを回復もしくは増強するための方法 |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
SI1935427T1 (en) | 2000-07-03 | 2018-05-31 | Bristol-Myers Squibb Company | USE OF HEATED CTLA4 MUTANT MOLECULES |
US6977072B2 (en) | 2000-10-27 | 2005-12-20 | Irx Therapeutics, Inc. | Vaccine immunotherapy for immune suppressed patients |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
US7105328B2 (en) | 2001-04-02 | 2006-09-12 | Dana-Farber Cancer Institute | Methods for screening for compounds that modulate pd-1 signaling |
MXPA03010568A (es) | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
WO2003020904A2 (en) * | 2001-08-31 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of generating human cd4+ th1 cells |
WO2003004625A1 (en) * | 2001-07-02 | 2003-01-16 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Methods of generating human cd4+ th2 cells and uses thereof |
US7718196B2 (en) | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
ES2542888T3 (es) | 2001-08-24 | 2015-08-12 | Uvic Industry Partnerships Inc. | Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata |
TW200502391A (en) * | 2003-05-08 | 2005-01-16 | Xcyte Therapies Inc | Generation and isolation of antigen-specific t cells |
WO2005007116A2 (en) * | 2003-07-18 | 2005-01-27 | Valeocyte Therapies Llc | Artificial antigen presenting cell devices |
EP1776583A4 (en) * | 2004-02-26 | 2009-04-29 | Immunovative Therapies Ltd | PROCESSES FOR THE PREPARATION OF T CELLS FOR CELL THERAPY |
DK1749090T3 (en) * | 2004-03-01 | 2017-09-04 | Immunovative Therapies Ltd | CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION |
WO2006138670A2 (en) * | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
US7993660B2 (en) | 2007-11-28 | 2011-08-09 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
JP5464641B2 (ja) * | 2008-01-21 | 2014-04-09 | 国立大学法人 東京大学 | 制御性t細胞製造方法及び制御性t細胞増幅装置 |
WO2009151496A2 (en) * | 2008-03-26 | 2009-12-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, | Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells |
CN108484767B (zh) | 2008-09-26 | 2022-01-14 | 达纳-法伯癌症研究公司 | 人抗pd-1、pd-l1和pd-l2的抗体及其应用 |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
JP5797190B2 (ja) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス, インコーポレイテッド | ワクチン免疫療法 |
WO2011060272A2 (en) | 2009-11-13 | 2011-05-19 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
CN107050430B (zh) | 2009-12-08 | 2021-10-15 | 伊尔克斯治疗有限公司 | 逆转朗格汉斯细胞免疫抑制的方法 |
CA3079122A1 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CA2800257C (en) | 2010-05-26 | 2019-03-05 | The Board Of Trustees Of The University Of Illinois | Personal glucose meters for detection and quantification of a broad range of analytes |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
WO2012097000A1 (en) | 2011-01-10 | 2012-07-19 | Pingda Ren | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
EP2734530A1 (en) | 2011-07-19 | 2014-05-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CN104619722B (zh) | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2014022759A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
EP3004877A4 (en) | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
CA2916865A1 (en) * | 2013-06-24 | 2014-12-31 | Anthrogenesis Corporation | Methods of expanding t cells |
ES2612918T3 (es) | 2013-07-10 | 2017-05-19 | Miltenyi Biotec Gmbh | Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
DK3052485T3 (da) | 2013-10-04 | 2021-10-11 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser og anvendelser deraf |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PE20170254A1 (es) | 2013-12-24 | 2017-04-12 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
MY184699A (en) | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
CN107073109B (zh) | 2014-06-11 | 2021-08-06 | 凯西·A·格林 | Vista激动剂和拮抗剂抑制或增强体液免疫的用途 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
US11220545B2 (en) | 2014-12-08 | 2022-01-11 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
EP3091032A1 (en) | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
TW202216201A (zh) | 2016-02-12 | 2022-05-01 | 比利時商楊森製藥公司 | 抗vista抗體及片段、其用途及鑑定其之方法 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
KR20190080825A (ko) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도 |
EP3439685B1 (en) * | 2016-04-08 | 2023-07-05 | Emory University | Methods of treating cancer and infectious diseases using cell based therapies |
MX2018012469A (es) | 2016-04-15 | 2019-07-04 | Immunext Inc | Anticuerpos vista antihumanos y uso de los mismos. |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11320431B2 (en) | 2016-06-28 | 2022-05-03 | Technische Universitaet Muenchen | Combination of reversible and irreversible cell labeling for analizing receptor-ligand koff rate |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
MA46053A (fr) | 2016-08-26 | 2019-07-03 | Juno Therapeutics Inc | Procédés de dénombrement de particules présentes dans une composition cellulaire |
US11866465B2 (en) | 2017-04-27 | 2024-01-09 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
JP7335883B2 (ja) | 2018-02-28 | 2023-08-30 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物中に存在する粒子を検出するための方法 |
WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
EP3847188A1 (en) | 2018-09-03 | 2021-07-14 | Technische Universität München | A double peptide tag combining reversibility and flexible functionalization |
BR112021008133A2 (pt) | 2018-10-31 | 2021-10-05 | Juno Therapeutics Gmbh | Métodos para seleção e estimulação de células e aparelhos para os mesmos |
US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
EP4051402A1 (en) | 2019-10-30 | 2022-09-07 | Juno Therapeutics GmbH | Cell selection and/or stimulation devices and methods of use |
EP4103203A1 (en) | 2020-02-12 | 2022-12-21 | Juno Therapeutics, Inc. | Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
BR112022015236A2 (pt) | 2020-02-12 | 2022-09-20 | Juno Therapeutics Inc | Composições de células t do receptor de antígeno quimérico direcionado a cd19 e métodos e usos das mesmas |
KR20240018454A (ko) | 2021-05-06 | 2024-02-13 | 주노 테라퓨틱스 게엠베하 | T 세포의 자극 및 형질도입 방법 |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
EP4227423A1 (en) | 2022-02-09 | 2023-08-16 | Technische Universität München | Means and methods for identifying high affinity t-cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
ZA91463B (en) * | 1990-01-25 | 1992-09-30 | Bristol Myers Squibb Co | Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody |
JPH06508501A (ja) * | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | B細胞上のcd28レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 |
ATE272708T1 (de) * | 1992-04-07 | 2004-08-15 | Univ Michigan | Immunregulation über die cd28-route |
-
1994
- 1994-06-03 JP JP7501964A patent/JPH08511166A/ja active Pending
- 1994-06-03 WO PCT/US1994/006255 patent/WO1994029436A1/en active IP Right Grant
- 1994-06-03 EP EP94919346A patent/EP0700430B1/en not_active Expired - Lifetime
- 1994-06-03 AU AU70521/94A patent/AU7052194A/en not_active Abandoned
- 1994-06-03 EP EP20050001589 patent/EP1553168A3/en not_active Withdrawn
- 1994-06-03 CA CA2164226A patent/CA2164226C/en not_active Expired - Lifetime
- 1994-06-03 AT AT94919346T patent/ATE293686T1/de active
- 1994-06-03 DK DK94919346T patent/DK0700430T3/da active
- 1994-06-03 DE DE69434342T patent/DE69434342T2/de not_active Expired - Lifetime
- 1994-06-03 ES ES94919346T patent/ES2240962T3/es not_active Expired - Lifetime
- 1994-06-03 PT PT94919346T patent/PT700430E/pt unknown
-
1998
- 1998-12-28 HK HK98116086A patent/HK1014734A1/xx not_active IP Right Cessation
-
2004
- 2004-06-16 JP JP2004178583A patent/JP4009618B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0700430A1 (en) | 1996-03-13 |
DE69434342T2 (de) | 2006-03-16 |
JPH08511166A (ja) | 1996-11-26 |
CA2164226A1 (en) | 1994-12-22 |
EP0700430B1 (en) | 2005-04-20 |
EP1553168A3 (en) | 2011-04-06 |
DE69434342D1 (de) | 2005-05-25 |
DK0700430T3 (da) | 2005-08-15 |
JP2004267220A (ja) | 2004-09-30 |
AU7052194A (en) | 1995-01-03 |
JP4009618B2 (ja) | 2007-11-21 |
ATE293686T1 (de) | 2005-05-15 |
ES2240962T3 (es) | 2005-10-16 |
CA2164226C (en) | 2011-02-08 |
HK1014734A1 (en) | 1999-09-30 |
WO1994029436A1 (en) | 1994-12-22 |
EP1553168A2 (en) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT700430E (pt) | Processo para estimular selectivamente a proliferacao das celulas t | |
NO911720L (no) | Fremgangsmaate og innretning for avviksboring. | |
BR8901991A (pt) | Processo e dispositivo de ativacao de combustivel | |
EP0326701A3 (en) | Piezoelectric shockwaves source | |
KR960000805U (ko) | 활자의 고정 및 정렬수단이 구비된 고무인장용 조판대 | |
PT91950A (pt) | Processo e dispositivo para concentrar solucoes | |
BR8907630A (pt) | Processo e instalacao para o esticamento de couro | |
DE59406583D1 (de) | Vorrichtung zum Rückenrunden von Buchblocks | |
PT89070A (pt) | Processo e dispositivo para trituracao fina | |
ITMI920627A1 (it) | Processo di cracking in presenza di solvente donatore di idrogeno | |
BR8806381A (pt) | Dispositivo e processo alimentador de tachas | |
NO883329L (no) | Anordning og fremgangsmaate for reduksjon av kjelestensdannelse i tremasse-prosesser. | |
DE59003199D1 (de) | Vorrichtung zur Aufnahme von Notschlüsseln. | |
FR2613863B1 (fr) | Dispositif audiovisuel extra plat | |
ES2022741B3 (es) | Procedimiento e instalacion para el montaje de las correas en los accionamientos por poleas. | |
BR8902192A (pt) | Processo para o aperfeicoamento da base adesiva para acabamentos de couro e utilizacao de poliacrilatos contendo grupos amino | |
BR8907514A (pt) | Aparelho e processo para cromar artigos | |
KR890014586U (ko) | 광디스크의 로딩 및 클램핑장치 | |
IT211407Z2 (it) | Procedimento fisico-chimico perristauri e riparazioni su pelle e vinilpelle. | |
IT209892Z2 (it) | Apparecchio abbronzante con testa perfezionata. | |
BR6702832U (pt) | Disposicao construtiva em dispositivo para individualidade de frascos e garrafas | |
BR6702303U (pt) | Painel para obtencao de numeros e letras | |
BR9106317A (pt) | Processo e disposicao para multiplexacao flexivel | |
NO890162L (no) | Anordning og fremgangsmaate for skrivning. | |
IT8005104V0 (it) | Supporto, in particolare per custodie di microtelefoni e/o per dischi combinatori, e/o per tastiere di selezione, e/o per mezzi di visualizzazione, e/o per fascette |